Q4 2022 Results

Company overview Financial review 2023 priorities Appendix FINANCIAL PROFILE 2022 performance continues our track record of consistent top-line growth and core margin expansion for Innovative Medicines (IM) IM Sales1 USD bn, % CAGR CC +5% IM Core Oplnc¹ USD bn, % CAGR CC +10% 42.0 15.2 15.2 41.3 39.0 37.7 13.6 12.7 +4% +6% +4% CC CC CC +11% +10% +8% CC CC CC IM Core Margin¹ (%), growth bps cc 33.5 +220bps 35.0 +130bps +130bps 36.9 36.2 FY 2019 FY 2020 FY 2021 FY 2022 FY 2019 FY 2020 FY 2021 FY 2022 FY 2019 FY 2020 FY 2021 FY 2022 1.2022 FY Sales growth +4% cc and -2% USD, 2022 FY Core Oplnc growth +8% cc and 0% USD. 36 Investor Relations | Q4 2022 Results NOVARTIS | Reimagining Medicine

View entire presentation